Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Skye Bioscience, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Skye Bioscience securities is from November 4, 2024, to October 3, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company [3]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Skye Bioscience made materially false and misleading statements regarding its business and the effectiveness of its product, nimacimab [4]. - Specifically, it is claimed that nimacimab was less effective than represented, and its clinical and commercial prospects were overstated [4]. - The lawsuit asserts that these misleading statements resulted in investor damages when the true information became public [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant financial losses for investors [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Skye between November 4, 2024, and October 3, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false statements about nimacimab's effectiveness and overstating its clinical and commercial prospects [5]. - On October 6, 2025, Skye announced that its nimacimab did not achieve the primary endpoint of weight loss in a clinical study, leading to a 60% drop in stock price, closing at $1.90 per share [6]. Group 3: Investor Communication - Faruqi & Faruqi encourages anyone with information regarding Skye's conduct, including whistleblowers and former employees, to contact the firm [8].

Core Viewpoint - Skye Bioscience, Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding the efficacy of its product, nimacimab [1][2]. Summary by Sections Class Action Details - The class period for the lawsuit is from November 4, 2024, to October 3, 2025, with a deadline for lead plaintiff appointments set for January 16, 2026 [2]. - The complaint alleges that Skye's public statements were materially misleading, as the company failed to demonstrate the efficacy of nimacimab as previously claimed [2]. Shareholder Participation - Shareholders who purchased shares during the specified class period are encouraged to contact the DJS Law Group to participate in the lawsuit [3]. - There is no cost or obligation for shareholders to enroll in the case, and they will receive updates through a portfolio monitoring software [3]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4].

Core Viewpoint - Skye Bioscience, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between November 4, 2024, and October 3, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding the effectiveness of the Company's lead product candidate, nimacimab, which was allegedly less effective than represented [2] - It is asserted that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to materially false and misleading public statements by the defendants [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3] Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Points - Skye Bioscience, Inc. is a clinical stage biopharmaceutical company focused on developing molecules targeting G protein-coupled receptors to treat obesity and metabolic diseases, with nimacimab as its lead product candidate [1] - A class action lawsuit has been filed on behalf of investors who acquired Skye securities between November 4, 2024, and October 3, 2025, alleging that the company misled investors about the viability of nimacimab [1][2] - The lawsuit claims that during the class period, Skye failed to disclose that nimacimab was less effective than represented, leading to overstated clinical and commercial prospects [2] Company Developments - On October 6, 2025, Skye released topline data from its 26-week Phase 2a CBeyond™ study of nimacimab, revealing that the drug did not achieve the primary endpoint of weight loss compared to placebo, and indicated lower than expected drug exposure [3] - Following the announcement, Skye's stock price dropped by $2.85 per share, or 60%, closing at $1.90 per share on the same day [3] Legal Actions - Shareholders interested in participating in the class action must submit their papers by January 16, 2026, to serve as lead plaintiff, representing other class members in the litigation [4] - Shareholders are not required to participate in the case to be eligible for recovery, and can choose to remain absent class members [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant stock price declines [2][5][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Skye between November 4, 2024, and October 3, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false and misleading statements about nimacimab's effectiveness and overstating its clinical and commercial prospects [5]. - On October 6, 2025, Skye announced that nimacimab did not achieve its primary endpoint in a clinical study, leading to a 60% drop in stock price, closing at $1.90 per share [6]. Group 3: Investor Participation - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member, with no impact on their ability to share in any recovery [7]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Skye's conduct [8].

Core Viewpoint - A class action securities lawsuit has been filed against Skye Bioscience, Inc. due to alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the company's lead product candidate, nimacimab, was less effective than previously represented, leading to overstated clinical, regulatory, and commercial prospects [3]. - Defendants are accused of making materially false and misleading public statements regarding the effectiveness and prospects of nimacimab [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Skye Bioscience, Inc. securities during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and business practices [1][5]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between November 4, 2024, and October 3, 2025, and aims to address alleged misleading statements made by the company regarding its product, nimacimab [1][5]. - Investors who purchased Skye securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Allegations Against Skye Bioscience - The lawsuit claims that Skye Bioscience made materially false and misleading statements about its business operations and the effectiveness of nimacimab, which were overstated [5]. - Specific allegations include that nimacimab was less effective than claimed, and that the company's clinical, regulatory, and commercial prospects were misrepresented [5]. Group 3: Legal Representation - Investors interested in joining the class action can do so by contacting Rosen Law Firm through their website or phone [3][6]. - It is noted that no class has been certified yet, and investors are advised they may select their own counsel or remain absent from the class [7]. Group 4: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in terms of securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/skye-bioscience-inc-loss-submission-form/?id=178595&from=3  CLASS PERIOD: No ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE:https://securitiesclasslaw.com/securities/skye-bioscience-inc-loss-submission-form/? ...